Pharma BD Deal Intelligence
A sub-scale diversification bolt-on whose marquee pipeline asset was serially rejected by the FDA and never became more than a niche product line, inside a company that itself later collapsed into opioid-liability bankruptcy.
Full analysis, sources & comparables →Endo's $370M cash bid plus up to $267M milestones for Indevus diversifies the buyer well beyond pain into urology and endocrinology specialty franchises.
On closing, Indevus becomes a wholly owned Endo subsidiary, with Sanctura/Sanctura XR, Vantas, Supprelin LA, Delatestryl, and a near-term Valstar relaunch…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Announced Jan 5, 2009; closed Feb 2009. $370M cash + up to $267M milestones. Urology/endo/oncology (Vantas, Valstar). Source: SEC 8-K, Fierce Biotech.
A sub-scale diversification bolt-on whose marquee pipeline asset was serially rejected by the FDA and never became more than a niche product line, inside a company that itself later collapsed into opioid-liability bankruptcy.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo Pharmaceuticals Inc. / Indevus Pharmaceuticals, Inc. (this deal) | 2009 | $370M | 33 |
| Endo Pharmaceuticals Inc. / Algos Pharmaceutical Corporation | 2000 | $250M | 34 |
| Endo Pharmaceuticals Inc. / SkyePharma plc | 2003 | $120M | 17 |
| Endo Pharmaceuticals Inc. / HealthTronics, Inc. | 2010 | $223M | 17 |
| Endo Pharmaceuticals Inc. / Qualitest Pharmaceuticals | 2010 | $1.2B | 17 |
| Endo Pharmaceuticals Inc. / American Medical Systems Holdings, Inc. | 2011 | $2.9B | 13 |
| Endo Pharmaceuticals Inc. / Penwest Pharmaceuticals Co. | 2010 | $144M | 13 |